欧林生物股价涨5.1%，富荣基金旗下1只基金重仓，持有1.72万股浮盈赚取2.24万元

Group 1 - The core point of the article highlights the recent performance of Olin Biological, which saw a 5.1% increase in stock price, reaching 26.80 yuan per share, with a total market capitalization of 10.879 billion yuan [1] - Olin Biological, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with the majority of its revenue coming from the adsorbed tetanus vaccine at 90.99% [1] - The company also generates revenue from other vaccines, including A group C group meningococcal polysaccharide conjugate vaccine (4.49%), b-type Haemophilus influenzae type b conjugate vaccine (3.99%), and others [1] Group 2 - From the perspective of fund holdings, Olin Biological is a significant investment for the Fuyong Fund, with its Fuyong Medical Health Mixed Fund A (015655) holding 17,200 shares, representing 2.06% of the fund's net value [2] - The fund has seen a floating profit of approximately 22,400 yuan from this investment, with a total fund size of 11.8186 million yuan [2] - Year-to-date, the fund has achieved a return of 14.22%, with a one-year return of 10.55%, although it has experienced a loss of 20.8% since its inception [2]